<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209244</url>
  </required_header>
  <id_info>
    <org_study_id>H-19054660</org_study_id>
    <nct_id>NCT04209244</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Effect of Fish Oil Versus Placebo on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Child Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lymphoblastic leukemia (ALL) is the most common malignant disease among children.
      Treatment results have improved over time due to intensive risk-adapted therapy and the
      5-year survival rate is now above 90%. However, the burden of therapy has increased
      proportionally. Many children develop serious acute and chronic side effects, which impact on
      the patients expected lifespan and impair their quality of life as a result of therapy.
      Treatment with PEG-asparaginase and dexamethasone increases the levels of triglycerides and
      total cholesterol. Consequently, the incidence of hyperlipidemia is high during initial ALL
      therapy. Studies have suggested that hyperlipidemia is a risk factor for development of
      osteonecrosis, thrombosis and possibly acute pancreatitis.

      Long-chained marine omega-3 fatty acids, found in fish oil, decrease levels of triglycerides
      and total cholesterol in hyperlipidemic patients. Due to the high survival rate, it is of
      great interest to develop methods to reduce treatment related toxicities.

      The investigators hypothesise that daily intake of fish oil will prevent development of
      hyperlipidemia during ALL treatment phases with dexamethasone and PEG-asparaginase compared
      to placebo and that fish oil intake may reduce the incidence of severe adverse events related
      to ALL treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>From treatment day 4 until treatment day 169 or 204</time_frame>
    <description>Triglycerides and/or total cholesterol levels five times or more than the age-dependent upper normal limit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>VLR and IR-low: 4, 11, 18, 25, 32, 39, 46, 53, 60, 67, 81, 95, 109, 123, 137, 151 and 169. IR-high: treatment day 4, 11, 18, 25, 32, 39, 46, 53, 60, 67, 74, 81, 88, 95, 102, 109, 123, 137, 151, 165, 179, 193 and 204.</time_frame>
    <description>Triglycerides, total cholesterol, VLDL-cholesterol, LDL-cholesterol and HDL-cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>From treatment day 4 until end of intervention (treatment day 169 or 204)</time_frame>
    <description>Assessed by self-registration forms, return of bottles and levels of EPA+DHA in whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>DEXA-scan at start and end of intervention. Bone biomarkers at treatment day 4, 81 and 169 for VLR and treatment day 4, 102 and 204 for IR-low and IR-high.</time_frame>
    <description>Assessed by DEXA-scan and bone biomarkers (iCa, PTH, vit D, phosphate, magnesium, creatinine, alkaline phosphatase, CTX, P1NP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic status</measure>
    <time_frame>At treatment day 4, 81 and 169 for VLR and at treatment day 4, 102 and 204 for IR-low and IR-high</time_frame>
    <description>Thromboelastography (TEG), multiplate and thrombocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>At treatment day 4, 81 and 169 for VLR and at treatment day 4, 102 and 204 for IR-low and IR-high</time_frame>
    <description>sTM, syndecan-1, PECAM, VEGFR1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe adverse events</measure>
    <time_frame>From treatment day 4 until end of intervention (treatment day 169 or 204)</time_frame>
    <description>Cumulative incidence of osteonecrosis, asparaginase associated pancreatitis and thrombosis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Milder side effects</measure>
    <time_frame>At end of intervention (day 169 or 204)</time_frame>
    <description>Assessed by questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dietary intake</measure>
    <time_frame>At treatment day 4, 81 and 169 for VLR and at treatment day 4, 102 and 204 for IR-low and IR-high</time_frame>
    <description>Assessed by 3-day food records</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Rapeseed Oil, 10 ml per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eskimo-3 Pure Fish Oil</intervention_name>
    <description>Dosage: 10 ml/day (2.6 g EPA+DHA)</description>
    <arm_group_label>Fish oil</arm_group_label>
    <other_name>Fish Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rapeseed Oil</intervention_name>
    <description>Dosage: 10 ml/day (0 g EPA+DHA)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children (1-17.9 years) and young adults (18-45 years) diagnosed with ALL, stratified
             to very-low risk (VRL), intermediate risk low (IR-low) and intermediate risk high
             (IR-high) in the ALLTogether protocol.

        Exclusion Criteria:

          -  Patients diagnosed with ALL, stratified to high risk (HR) after induction treatment or
             stem cell transplantation in the ALLTogether protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Leth Frandsen</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renate Dagsdottir Laumann, MSc</last_name>
    <phone>+4560163957</phone>
    <email>renate.dagsdottir.laumann@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steen Rosth√∏j, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birgitte Klug Albertsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renate Dagsdottir Laumann, MSc</last_name>
      <phone>+4560163957</phone>
      <email>renate.dagsdottir.laumann@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peder Skov Wehner, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Renate Dagsdottir Laumann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

